How to Check Whether Your Blood Pressure Medicine Is Affected by a Recall

If you have seen a warning about recalled blood pressure medicine, do not assume every pack of that drug is affected. In the United Kingdom, a recall often concerns a particular manufacturer, strength and batch rather than every prescription with the same ingredient. Check the official Medicines and Healthcare products Regulatory Agency (MHRA) notice, compare it with your packaging and ask your pharmacist before changing treatment.

Information checked November 3, 2026: The MHRA issued a UK recall on October 29, 2026 for one batch of Accord-UK lercanidipine hydrochloride 10 mg tablets. This article explains that confirmed example and a method for checking any blood pressure prescription. It does not mean all lercanidipine or other blood pressure medicines have been recalled.

Where do you check for an official UK medicine recall?

Start with the MHRA alerts, recalls and safety information service on GOV.UK. Search the medicine name and select the medicines recall/notification category. Open the original notice, not just a headline or social media screenshot. Note its issue date, manufacturer, exact medicine name, strength, batch numbers and instructions specifically addressed to patients. A notice aimed at pharmacies may require different action from a patient-level recall.

Search results and old news articles can remain online after a notice is issued. A US Food and Drug Administration announcement also does not, by itself, establish that a UK-supplied pack is affected. If the country or product description differs, check with a UK pharmacist instead of applying another country's instructions.

What details should you compare on the medicine pack?

1. Medicine and ingredient: Read the label and confirm the active ingredient, not only the brand name.
2. Strength and form: Compare 5 mg, 10 mg or another strength, and whether the product is a tablet or capsule.
3. Manufacturer: Find the manufacturer or marketing authorization holder named in the alert. Generic products can have different suppliers.
4. Batch or lot number: Check the carton and blister foil for a batch code. The pharmacy dispensing label is not always the manufacturer's batch identifier.
5. Expiry and pack size: Compare these if the notice specifies them.
6. Contents: If the alert describes incorrect blister strips, compare the printed blister strength with the carton without taking an uncertain tablet.

If you discarded the carton or cannot read the batch number, contact the dispensing pharmacy. They may be able to help identify the supplier and affected stock. Do not identify a tablet by color alone: appearances can vary, and a packaging mix-up can involve different strengths.

Which blood pressure medicine was included in the October 29 UK recall?

The MHRA Class 2 recall EL(26)A/45 identifies Accord-UK Ltd lercanidipine hydrochloride 10 mg film-coated tablets, batch M2510877, expiry 11/2028, in packs of 28. The notice says a sealed 10 mg carton was reported to contain one correct 10 mg blister strip and one 20 mg blister strip, with the latter marked batch M2510831. The recall applies at pharmacy and wholesaler level; the regulator describes the reported occurrence and anticipated risk as low.

If your Accord 10 mg carton carries batch M2510877: inspect the text on each blister. According to the MHRA, if all strips say lercanidipine 10 mg, no further action is required and you may continue taking those tablets. If a strip says lercanidipine 20 mg, do not take the medicine from that incorrect strip; contact your pharmacy for the correct supply. If you believe you took the 20 mg tablets and have dizziness, headache, flushing, palpitations or other symptoms, seek immediate medical advice. Bring the packaging, leaflet and remaining tablets when seeking help.

The affected batch number is an identification tool, not proof that every carton contains an incorrect strip. Equally, the recall does not cover every brand or strength of lercanidipine. Compare all the specified details rather than reacting to the medicine name alone.

Should you stop taking blood pressure medication because of a recall?

Do not stop or change your prescribed blood pressure treatment solely because you saw a recall headline. Stopping treatment can leave blood pressure uncontrolled, while taking a suspected incorrectly labeled dose can also cause harm. The appropriate next step depends on the precise notice and whether your own pack is affected. Follow the patient instructions in that notice and contact a pharmacist or prescriber promptly to arrange a safe, uninterrupted supply.

If you have a pack with a suspected incorrect strength, do not take the questionable tablets while waiting for clarification. Ask the pharmacy how to obtain the correct medicine and what to do about the next scheduled dose. Do not double a later dose to compensate for one missed without professional advice.

What if you already swallowed a tablet from a potentially affected pack?

Keep the carton and blister strips, record the dose and approximate time taken, and call your pharmacist, GP or NHS 111 for advice based on the actual product and symptoms. Do not take extra tablets or attempt to reverse the effect yourself. If someone collapses, has severe chest pain, severe breathing difficulty or signs of a stroke, call 999 for emergency help.

A recall is not proof that you have been harmed. Conversely, having no symptoms does not establish that the product or dose was correct. Your clinician can consider the specific medicine, other prescriptions, symptoms and blood pressure readings. If you monitor blood pressure at home, record readings accurately and share them with the clinician; do not use one reading to decide independently whether to stop therapy.

Does a Class 2 recall mean every patient must return their medicine?

No. Recall classes communicate the nature and urgency of a quality concern, but the scope of action is specified in the individual notice. The October 29 lercanidipine alert explicitly directs pharmacies and wholesalers to quarantine and return affected stock, while giving separate instructions for patients to inspect blister strips. It would be misleading to describe that as an instruction for every lercanidipine patient to stop treatment.

Another common misconception is that an alert naming a drug automatically covers all manufacturers. UK generic medicines may share an active ingredient but have different marketing authorization holders, batches and packaging. The practical check is always product plus manufacturer plus strength plus batch, followed by the precise patient advice.

How do you report a suspected problem or get a replacement?

Contact the pharmacy that supplied the prescription. Explain the medicine name, strength, manufacturer, batch number, expiry date and any mismatch between carton and blister. Ask whether the pack is affected, whether it should be returned and how to obtain a replacement without interrupting prescribed treatment. If your regular pharmacy is closed and the next dose is due, use NHS 111 or an available urgent pharmacy service for guidance.

Suspected adverse reactions can be reported through the MHRA Yellow Card scheme. Reporting supports medicine safety monitoring but does not replace medical attention. Keep photographs of the printed packaging details if useful, without sharing personal prescription labels publicly.

Quick checklist before your next dose

• Open the current MHRA notice on GOV.UK and confirm it concerns UK supplies.
• Match the medicine, manufacturer, strength, batch, expiry and pack size.
• Read the patient-specific instructions, not only the recall classification.
• Check carton and blister labeling when a packaging mix-up is reported.
• Ask your pharmacist immediately if details match, are missing or conflict.
• Seek medical help promptly if you may have taken an incorrect dose or have symptoms.

Bottom line: The verified October 29, 2026 UK alert concerns a defined batch of Accord-UK lercanidipine 10 mg, not every blood pressure prescription. A few minutes comparing your actual pack with the original MHRA notice can establish what is known; your pharmacist can resolve what remains uncertain and help maintain safe treatment.